Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
KIR2DS3 Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 2DS3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR2DS3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KIR2DL5B Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 2DL5B Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR2DL5B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KIR2DS1 Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 2DS1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR2DS1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KIR2DL3 Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 2DL3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR2DL3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KIR2DL2 Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 2DL2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR2DL2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KIR2DL5A Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 2DL5A Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR2DL5A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KIR2DL4 Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 2DL4 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR2DL4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IRAK1BP1 Biologics Sequence Review Report 2026: Interleukin-1 receptor-associated kinase 1-binding protein 1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of IRAK1BP1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KIR2DL1 Biologics Sequence Review Report 2026: Killer cell immunoglobulin-like receptor 2DL1 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of KIR2DL1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IRAK3 Biologics Sequence Review Report 2026: Interleukin-1 receptor-associated kinase 3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of IRAK3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IRAK4 Biologics Sequence Review Report 2026: Interleukin-1 receptor-associated kinase 4 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of IRAK4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GRB7 Biologics Sequence Review Report 2026: Growth factor receptor-bound protein 7 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of GRB7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.